EGFR and glioblastoma: Lapatinib, an inhibitor of both EGFR and HER2 TKs, showed little effect in a phase I/II clinical trial [75], but in combination therapy with CUDC-101, an HDAC inhibitor, it enhanced the radiosensitivity of the GBM cell line in vitro [76].